Research analysts who have asked questions during Can-Fite BioPharma earnings calls.
JK
Jason Kolbert
D Boral Capital
2 questions for CANF
Also covers: BCDA, HUMA, IVVD +6 more
VB
Vernon Bernardino
H.C. Wainwright & Co.
2 questions for CANF
Also covers: ELDN, GALT, GOVX +6 more
Peter Levine
Evercore ISI
1 question for CANF
Also covers: CGNT, CRWD, EGHT +7 more
RM
Ralph Martini
Private Investor
1 question for CANF
Recent press releases and 8-K filings for CANF.
Can-Fite BioPharma Announces Reverse Stock Split and ADS Ratio Change
CANF
Delisting/Listing Issues
- Can-Fite BioPharma Ltd. announced a 1-for-3,000 reverse split of its ordinary shares, approved by shareholders on November 10, 2025, and effective on the Tel-Aviv Stock Exchange on January 2, 2026.
- Concurrently, the company will change its American Depositary Share (ADS) ratio from one ADS representing 300 ordinary shares to one ADS representing 2 ordinary shares, effective on the NYSE American on January 5, 2026.
- This ADS ratio change will effectively result in a one-for-twenty ADS split for ADS holders, requiring them to exchange every twenty current ADSs for one new ADS.
- The total outstanding ordinary shares will be reduced at a three thousand-for-one ratio, and the authorized ordinary shares will decrease from 42,000,000,000 to 14,000,000.
Dec 23, 2025, 9:50 PM
Can-Fite BioPharma Provides Clinical and Financial Status Update
CANF
Guidance Update
New Projects/Investments
Earnings
- Can-Fite BioPharma Ltd. is currently enrolling patients in pivotal Phase III clinical studies for Namodenoson in advanced hepatocellular carcinoma (HCC) and Piclidenoson for psoriasis, with interim analysis data expected in approximately Q4 2026 and Q2 2026, respectively.
- The company is also enrolling patients in a Phase IIb study of Namodenoson for metabolic dysfunction-associated steatohepatitis (MASH) and expects data from a Phase IIa study of Namodenoson in pancreatic cancer during the second quarter of 2026.
- As of June 30, 2025, Can-Fite had $6.45 million in cash and cash equivalents and short-term deposits, and subsequently raised $5 million through a public offering in July 2025 and $2.2 million via its ATM facility in November 2025.
Dec 16, 2025, 2:21 PM
Can-Fite BioPharma's CF602 Erectile Dysfunction Treatment Receives Brazilian Patent Allowance
CANF
New Projects/Investments
- Can-Fite BioPharma Ltd. announced it received a Notice of Allowance from the National Institute of Industrial Property of Brazil for a patent application related to its CF602 drug candidate for erectile dysfunction (ED).
- The patent, titled "An A3 Adenosine Receptor Ligands For Use in Treatment of a Sexual Dysfunction," expands the intellectual property protection for CF602 in ED beyond the U.S. and Europe.
- CF602 is being developed as an oral or topical treatment for ED patients living with diabetes and those who are non-responders to current ED drugs like Viagra and Cialis.
- This addresses a significant unmet need, as an estimated 30% to 35% of ED patients are non-responders to existing treatments, and these drugs can be contraindicated for approximately 16 million men living with diabetes in the U.S., within a $3.2 billion ED market.
Nov 20, 2025, 12:02 PM
Can-Fite BioPharma Reports 9-Year Survival in Liver Cancer Patient Treated with Namodenoson
CANF
New Projects/Investments
- Can-Fite BioPharma Ltd. announced on November 18, 2025, that a patient with advanced liver cancer treated with Namodenoson has achieved 9 years of overall survival with a complete cure.
- This patient, who was part of a completed Phase II study, continues treatment through a compassionate use program and remains cancer-free.
- The company is actively enrolling patients in Israel, Europe, and the U.S. for a pivotal Phase III clinical study of Namodenoson for advanced hepatocellular carcinoma (HCC) as a 2nd or 3rd line treatment.
- Namodenoson has been granted Orphan Drug status by both the U.S. FDA and European Medicines Agency (EMA), and Fast Track Status by the FDA for HCC treatment.
Nov 18, 2025, 12:01 PM
Can-Fite BioPharma Ltd. to Hold Special General Meeting for Capital Increase and Reverse Stock Split
CANF
Delisting/Listing Issues
- Can-Fite BioPharma Ltd. will hold a Special General Meeting of Shareholders on November 3, 2025, at 3:00 p.m. Israel time.
- Shareholders will vote on a proposal to increase the Company's authorized share capital by 22,000,000,000 ordinary shares, resulting in a total authorized share capital of 42,000,000,000 ordinary shares.
- A second proposal is to approve a reverse split of the Company's ordinary shares at a ratio of one (1) ordinary share for three thousand (3,000) ordinary shares. This is recommended due to a decline in share price to make shares more attractive to investors.
- The Board of Directors unanimously recommends a vote "FOR" each of the proposals.
Oct 3, 2025, 8:15 PM
Can-Fite BioPharma Reports Complete Resolution of Esophageal Varices with Namodenoson
CANF
New Projects/Investments
- Can-Fite BioPharma Ltd. announced the complete resolution of esophageal varices in a decompensated cirrhosis patient treated with Namodenoson under a compassionate use program.
- This clinical finding, confirmed by endoscopic evaluation, is an uncommon clinical outcome and may suggest a disease-modifying effect of Namodenoson for advanced liver disease.
- Namodenoson is currently being evaluated in a Phase III clinical trial for hepatocellular carcinoma (HCC), a Phase IIb trial for Metabolic Dysfunction-associated Steatohepatitis (MASH), and a Phase IIa study in pancreatic cancer.
- The U.S. market for liver cirrhosis treatment is projected to grow to approximately $15 billion by 2030, underscoring the urgent need for new therapies.
Sep 15, 2025, 11:10 AM
Can-Fite BioPharma Reports H1 2025 Financial Results and Clinical Updates
CANF
Earnings
New Projects/Investments
- Can-Fite BioPharma Ltd. reported a net loss of $4.87 million for the six months ended June 30, 2025, an increase from a net loss of $3.95 million in the prior year period. Revenues for the same period decreased by 36.07% to $0.20 million.
- As of June 30, 2025, the company had $6.45 million in cash and cash equivalents and short-term deposits. Subsequent to this date, in July 2025, Can-Fite completed a public offering, raising $5 million in gross proceeds.
- The company's Namodenoson drug candidate achieved over 50% enrollment in its Phase 2a pancreatic cancer study and received Orphan Drug Designation from the U.S. FDA for this indication. Additionally, Piclidenoson demonstrated potential as a treatment for vascular dementia in a study by UCLA.
- Can-Fite's history of net losses and operating cash outflows raise substantial doubt about its ability to continue as a going concern, though management expects existing financial resources to be sufficient for at least the next twelve months and plans to reduce non-essential expenses and defer certain R&D programs.
Aug 28, 2025, 12:49 PM
Quarterly earnings call transcripts for Can-Fite BioPharma.
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more